Trial Profile
A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Omacetaxine mepesuccinate (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors ChemGenex Pharmaceuticals
- 06 May 2014 According to ClinicalTrials.gov record, status changed from completed to discontinued.
- 07 May 2012 Company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.
- 08 Dec 2009 Primary endpoint 'Cytogenetic response rate' has been met.